Display options
Share it on

Cardiovasc Drugs Ther. 2016 Oct;30(5):537. doi: 10.1007/s10557-016-6684-z.

Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.

Cardiovascular drugs and therapy

Robert S Rosenson, Terry A Jacobson, David Preiss, Stephen C Djedjos, Ricardo Dent, Ian Bridges, Michael Miller

Affiliations

  1. Mount Sinai Heart, Cardiometabolics Unit, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, MC1 Level, New York, NY, 10029, USA. [email protected].
  2. Emory University, 201 Dowman Drive, Atlanta, GA, 30322, USA.
  3. Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LF, UK.
  4. Amgen Inc., One Amgen Center Dr, Thousand Oaks, CA, 91320, USA.
  5. Amgen (Europe) GmbH, Dammstrasse 23, 6300, Zug, Switzerland.
  6. Amgen Ltd, 240 Cambridge Science Park, Milton, Cambridge, CB4 0WD, UK.
  7. University of Maryland School of Medicine, 655 W Baltimore St, Baltimore, MD, 21201, USA.

PMID: 27497929 PMCID: PMC6828239 DOI: 10.1007/s10557-016-6684-z

[No abstract available.]

Publication Types